Introduction
Treatment of metastatic renal cell carcinoma (RCC) has evolved rapidly with the improved understanding of its molecular pathogenesis and the subsequent development of molecularly targeted agents. Three potentially distinct targets and therapeutic approaches are currently available; vascular endothelial growth factor (VEGF) pathway inhibition, mammalian target of rapamycin (mTOR) targeted therapy and immunotherapy. Randomized trials have demonstrated that agents targeting these pathways are active as single agents. However, these new agents have only been compared to either interferon-a or placebo and not compared to each other in randomized trials, although such trials are currently underway. Randomized phase III trials have provided evidence for the 'average' patient but data are lacking to help guide the choice of treatment more precisely for individual patients particularly in relation to histological type and clinical characteristics. The identification of optimal treatment strategies for particular patients with specific histopathological and molecular features will be an important focus for the next generation of trials in RCC. It is likely that this will involve the development of blood and tissue-based biomarkers as well as functional imaging parameters. Future trials will help answer questions about optimal sequencing and/or the most effective combination regimens. They will also address the potential role of these drugs in the neoadjuvant and adjuvant settings and more clearly define their efficacy in patients with advanced tumours of nonclear cell histology. This discussion focuses on the evidence for the efficacy and safety of sunitinib beyond the patient group studied in the pivotal trial by Motzer and colleagues [Motzer et al. 2007] .
Predictive factors for sunitinib response Clinical factors are currently used to guide treatment selection for patients with advanced RCC.
These factors include histology and the Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic risk category [Motzer et al. 2002a] , which includes performance status. There are no known predictive biomarkers for anti-angiogenic therapy currently available to help guide treatment selection [Duda et al. 2007] . Based on randomized controlled trials published to date, an 'evidence-based' algorithm has been created to guide treatment choice. For patients with clear-cell RCC, sunitinib or bevacizumab plus interferon-a are the frontline treatments in patients with favourable or intermediate prognostic factors, and temsirolimus the first-line treatment of choice in patients with poor prognostic factors [Escudier et al. 2008; Hudes et al. 2007; Motzer et al. 2007] . There is level 1 evidence [Harbour and Miller, 2001] for sorafenib in patients who have progressed after cytokine therapy, and everolimus is the preferred choice for patients who progress on VEGF-receptor targeted therapy. This algorithm has limitations. Firstly, it does not provide guidance for subgroups that were under-represented or excluded from the pivotal trials, e.g., those with poor prognosis features, patients with brain metastases and those who have not undergone nephrectomy. Secondly, trials have not been undertaken in less common clinical situations, e.g., those with nonclear cell histology, or poor performance score. Furthermore, we have only a relatively limited rather than extensive set of phase III trials. The role of sunitinib following failure of other VEGF receptor (VEGFR)-targeted therapies remains unclear. Sunitinib is clearly very active after cytokine failure as demonstrated in the original phase II studies.
Sunitinib in patients expected to tolerate treatment poorly In many countries getting access to more that one targeted agent is difficult because of financial constraints. In these areas, entry into a clinical trial is often the only means a patient can receive newer compounds. In the UK, prior to National Institute for Health and Clinical Excellence (NICE) approval for sunitinib as the first-line treatment of advanced RCC, many patients were treated with sunitinib on an expanded-access program (EAP). The value of an EAP is that for patients not eligible for a trial or those who do not have access to a trial may receive treatment prior to the drug becoming available. Entry criteria for EAPs are generally less rigid than those for phase III trials as they allow inclusion of patient subgroups not usually evaluated in phase III registration trials. The results of the sunitinib EAP have recently been published [Gore et al. 2009 ], providing valuable data to help guide the use of sunitinib in patient subgroups not included or under-represented in the pivotal phase III trial of sunitinib versus interferon-a [Motzer et al. 2007] .
The sunitinib EAP publication [Gore et al. 2009] reports data on safety, treatment duration, tumour response and survival for 4371 patients in a modified intention-to-treat population and included participants from 52 countries. The median number of treatment cycles was five and the median follow up was 11.6 months. The median progression free survival (PFS) and median overall survival (OS) were 10.9 months and 18.4 months respectively. The PFS endpoint for the EAP mirrors that reported in the pivotal phase III trial [Motzer et al. 2007 ], although given the inherent differences in the way randomized controlled phase III trials and EAPs are conducted, this result is of limited value as direct comparisons cannot be made. The overall response rate (ORR) reported in the EAP was 17%; lower than the 31% reported in the phase III trial [Motzer et al. 2007] . The EAP protocol did not specifically mandate assessment of response and this may have led to an underreporting of response. It is also possible that the relatively high rate of dose reductions in the EAP resulted in a lowering of the ORR given the evidence for a dose-response relationship with sunitinib [Houk et al. 2008] . The large sample size in the EAP has allowed analysis of underrepresented populations and provides valuable supportive evidence for the use of sunitinib beyond the patient group with Eastern Cooperative Oncology Group (ECOG) performance score of 1, good or intermediate MSKCC prognostic score and clear cell histology. The subgroups identified and reported from the EAP include patients with brain metastases, poor performance status, nonclear cell histology and of older age (65 years).
There appeared to be benefits in all four of the subgroups. In the 33% of patients who were aged 65 or older the ORR, PFS and OS were all comparable with the EAP study population as a whole. The three other subgroups had a poorer prognosis; however, the median survival in these subgroups was better than expected compared to historical controls: 320 patients with brain metastases, 503 patients with poor performance status and 588 patients with nonclear cell histology and they had a median OS of 9.2, 6.7 and 13.4 months, respectively, which compares to historical data of 4.06.0 [Culine et al. 1998 ], 4.8 [Motzer et al. 2004 ] and 9.4 [Motzer et al. 2002b ] months, respectively. These results suggest benefit can be achieved for these subgroups and that sunitinib can be justified in selected cases. In the patients with brain metastases, brain-specific tumour response and the timing of radiation therapy was not reported and questions remain to be answered regarding the management of this patient group with sunitinib and the other targeted agents. Radiation therapy continues to be standard practice, but it remains to be determined whether systemic therapy with a targeted agent such as sunitinib could be considered as an alternative, particularly for patients who have small asymptomatic brain metastases diagnosed incidentally. Similarly, studies need to be performed that evaluate the combination of targeted agents with radiotherapy. There are anecdotal reports of sunitinib having activity against brain metastases [Helgason et al. 2008; Medioni et al. 2007; Negrier, 2007] , and animal studies have shown that sunitinib or its active metabolite penetrates the central nervous system [Patyna and Peng, 2006 ]. Prospective trials focusing on patients with brain metastases as well as other patient groups are required to more clearly define the potential for benefit and comparative efficacy of sunitinib and other targeted agents such as the mTOR inhibitors.
Toxicity
The treatment-related adverse events reported in the sunitinib EAP [Gore et al. 2009 ] are consistent with those from previously reported trials [Motzer et al. 2009 [Motzer et al. , 2007 [Motzer et al. , 2006 . The most commonly reported non-haematological adverse events were diarrhoea, fatigue, nausea and mucosal inflammation. The most common grade 34 toxicities were fatigue, hand-foot syndrome, neutropaenia, thrombocytopaenia, asthenia, hypertension and diarrhoea. There was a relatively low incidence of grade 34 adverse events in the EAP, possibly because there was a relatively high rate of dose reduction. It is likely that troublesome grade 2 adverse events prompted dose reductions as these side effects occur at high frequency, tend to be persistent, difficult to manage and can significantly impair a patient's quality of life. The frequency of the most commonly reported grade 34 adverse events for patients with brain metastases, poor performance status, nonclear cell histology or age 65 years, did not differ markedly when compared to all patients and, only one of the 321 patients with brain metastases experienced a cerebral haemorrhage that was considered to be treatment related. Grade 3 or higher cardiac toxicity was reported in only 1% of patients, in keeping with findings from the phase III trial [Motzer et al. 2007] . Some uncertainty remains about the precise efficacy of sunitinib in these subgroups, particularly for patients with brain metastases, poor performance score or nonclear cell histology, but the EAP established that sunitinib is safe and has manageable toxicity in these patient subgroups. Conventional oncological teaching tells us that patients with poor performance status tolerate cytotoxic chemotherapy poorly and it needs to be modified or avoided in this circumstance [Schiller et al. 2002] . The EAP data suggest that targeted therapy is tolerated and provides benefit in these groups of patients. Similarly, patients with nonsmall cell lung cancer and poor performance score 2 have been reported to have a tolerability profile to gefitinib that is consistent with that reported in previous monotherapy studies [Goss et al. 2009 ].
Sunitinib in previously treated patients
In the sunitinib EAP, 68% patients received prior cytokine therapy and a higher proportion of these patients were classified as having poor risk disease on MSKCC criteria (11% vs 3%), compared to those who had no prior exposure to cytokines. There was negligible difference in the ORR, PFS and OS between patients with or without prior cytokine treatment. This suggests that prior treatment with cytokine therapy did not negatively impact on the efficacy of sunitinib and there may even be a group of patients who could derive initial benefit from cytokine therapy then further benefit from sequential treatment with a targeted agent such as sunitinib, although this would need to be tested in a prospective randomized trial. The tolerability of sunitinib may be poorer in patients with prior cytokine therapy as dose reduction occurred in 49% of patients compared to 43% of patients without prior cytokine treatment. However, it is more likely that this is related to the higher proportion of patients with prior cytokine therapy being classified as poor risk by the MSKCC criteria. There are also additional non-randomized data to support the use of sunitinib as a second-line therapy following cytokines. Combined analysis of two phase II trials reported outcome in 168 patients treated with sunitinib after prior cytokines. Results demonstrated a 45% ORR and a median PFS and OS of 8.4 and 22.3 months respectively [Rosenberg et al. 2007 ].
There are retrospective data to support the sequential use of sunitinib for patients who have progressed on a different VEGF-targeted therapy [Tamaskar et al. 2008 ], suggesting a degree of noncross-resistance between these agents. Patients with bevacizumab-refractory disease appear to achieve benefit from further treatment with either sunitinib or sorafenib. Non-randomized studies in this patient group have reported median PFS of 44.1 weeks [Rini et al. 2008] and 30.4 weeks [Drabkin et al. 2007] for sunitinib and sorafenib, respectively. There are insufficient data to determine whether the order in which targeted agents are sequenced makes any difference to outcome. Dudek and colleagues performed a retrospective study of 49 patients to compare the efficacy of sequential therapy with sorafenib followed by sunitinib versus sunitinib followed by sorafenib [Dudek et al. 2009 ]. In this study, the group treated with sorafenib followed by sunitinib had a statistically significant improvement in OS. Given this was a retrospective study with a small sample size, major conclusions cannot be made. It does however, highlight the need for further studies to answer questions about optimal sequencing, and such trials are underway.
Biomarkers of efficacy
There is a pressing need to identify markers for response and resistance in order to provide the most appropriate individually tailored sequence of anti-angiogenic therapies. High baseline serum VEGF levels have been associated with poor outcome; however it has not been shown to be useful in predicting benefit from sorafenib or bevacizumab [Escudier et al. 2008; Bukowski et al. 2007] . There are a number of potential biomarkers currently under investigation. Data from a phase II sunitinib trial in cytokinerefractory disease found larger changes in VEGF levels at day 28 in patients with response compared to stable disease or disease progression [Deprimo and Bello, 2007] . It has also been found that following treatment with pazopanib, a greater decrease in soluble VEGFR-2 level at day 14 therapy predicted a better outcome in terms of response and PFS [Hutson et al. 2008] . Low baseline levels of soluble VEGFR-3 and VEGF-C have been associated with longer PFS and better response in patients receiving sunitinib after progression on bevacizumab [Rini et al. 2008] . Further studies are required to determine if these tests will be able to distinguish early on in treatment those patients most likely to be resistant to VEGF inhibitor therapy. Hypoxia-inducible factor-1 alpha (HIF-1a) expression has been demonstrated to be an independent prognostic factor for patients with metastatic RCC [Klatte et al. 2007] . Investigations are underway to study HIF expression as a potential predictive marker for response to targeted therapy. Early reports suggest high levels of HIF-2 expression can predict response to sunitinib [Patel et al. 2008] . A further potential biomarker is the activation status of the von HippelLindau (VHL) gene. In view of the crucial role that VHL gene inactivation plays in RCC, VHL status has been analysed in 123 patients treated with VEGF-targeted agents [Choueiri et al. 2007] . Loss-of-function mutations in the VHL gene were identified as an independent prognostic factor associated with improved response. It was also found that patients treated with bevacizumab or sorafenib responded only if their VHL gene was inactivated, in contrast to patients treated with sunitinib or axitinib, who experienced responses irrespective of the activation status of the VHL gene. It remains unclear whether sunitinib and axitinib have additional non-VHLrelated antitumour effects and whether the VHL/HIF/VEGF pathway is the important therapeutic target in VHL wild-type RCC.
The safety and efficacy of sunitinib in the adjuvant and neoadjuvant settings remains investigational. Three large randomized studies are currently underway investigating the role of sunitinib as an adjuvant treatment. Sunitinib has a potential advantage over some of the other targeted agents in relation to neo-adjuvant therapy because of its relatively high ORR, which could be important if patients with inoperable locally advanced tumours are to be rendered operable. A small trial recently reported 4 of 19 patients with inoperable RCC successfully underwent nephrectomy following pre-operative sunitinib [Thomas et al. 2009 ]. In addition to the potential therapeutic benefit from this strategy, such studies will also be able to assess pretreatment and post-treatment tumour specimens which will help the future development of biomarkers of response and resistance.
Conclusion
Sunitinib has become established as a leading first-line systemic therapy available to patients with metastatic RCC. However, level 1 evidence [Harbour and Miller, 2001] is lacking for its safety and efficacy in patient groups underrepresented in the pivotal phase III trial. Results from non-randomized studies, in particular the recently published sunitinib EAP, provide evidence suggesting that sunitinib is tolerable and may provide benefit in subgroups of patients who might be expected to tolerate treatment poorly.
Efficacy is clearly seen in older patients and in those with a history of prior cytokine therapy. The potential for benefit in the poorer prognosis groups such as those with brain metastases, nonclear cell histology or poor performance score is less clear, although based on currently available data, sunitinib can be justified for selected patients in these circumstances. Prospective studies are needed to more clearly define the role of sunitinib in these subpopulations and to make comparisons with alternative treatment options. Non-cross resistance between sunitinib and other targeted agents has been established; however, there is little evidence to accurately guide optimal sequencing or combination strategies. Most importantly, further research is required to identify markers of response and resistance to therapy.
